As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...

M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing ...

A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Insitro’s layoffs affect about 65 employees as the AI-focused biotech looks to advance its pipeline in metabolic disease and ...

The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the ...

The oncologist and former University of California, San Francisco, professor has long been critical of COVID-19 mandates and ...